17 Current news of Epigenomics
rss01-09-2012
Epigenomics AG announced the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in The New England Journal of Medicine.In this study involving more than 200 patients in four independent ...
04-26-2011
Epigenomics AG announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny will start in his new position in early May 2011. Mr. Doheny has 30+ years of ...
10-08-2010
Epigenomics AG and NextPharma Technologies announced that the companies have signed a global manufacturing contract for Epigenomics' Epi proColon product. Epi proColon, currently marketed in Europe, is the world's first in-vitro diagnostic test for the detection of colorectal cancer in a ...
07-22-2010
Epigenomics AG reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., today has announced the launched of a laboratory-developed test for the blood-based detection of colorectal cancer. The test is based on Epigenomics' proprietary Septin9 biomarker and DNA ...
06-24-2010
Epigenomics AG successfully completed the pivotal performance evaluation study for its Epi proLung BL Reflex Assay, a lung cancer diagnostic test. The test determines the DNA methylation status of the SHOX2 gene in bronchial lavage material routinely obtained during the clinical workup of ...
05-04-2010
Epigenomics AG and Warnex Medical Laboratories, a division of Warnex Inc., announced that they have signed a non-exclusive licensing agreement for Epigenomics' colorectal cancer biomarker Septin9. Under the terms of the agreement, Warnex has obtained the rights to establish a ...
Patent broadly covers HeavyMethyl, a core technology of Epigenomics' molecular diagnostic products
03-15-2010
Epigenomics AG announced that it received a Notice of Allowance by the Japanese Patent Office stating that they intend to grant a patent for Epigenomics' HeavyMethyl(TM) technology. This notification is equivalent to a "Rule 71(3) notification" by the European Patent Office. Patent ...
11-04-2009
Epigenomics AG announced that Quest Diagnostics Incorporated successfully completed the clinical validation of its Septin9-based laboratory-developed test for aiding the detection of colorectal cancer. Under terms of a license agreement between the companies for Epigenomics' proprietary DNA ...
Biomarker mSHOX2 could accelerate diagnostic work-up of patients with suspected lung cancer
08-27-2009
Epigenomics AG announced that it successfully completed a clinical feasibility study in lung cancer. This study has confirmed Epigenomics' proprietary lead biomarker mSHOX2 for lung cancer diagnosis when tested in blood samples. In this study the amount of methylated DNA of the SHOX2 gene ...
ARUP to commercialize laboratory-developed blood test based on Epigenomics' mSEPT9 biomarker to aid in the early detection of colorectal cancer
08-14-2009
Epigenomics AG announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, U.S. based ARUP Laboratories, Inc. (ARUP). Under the agreement, ARUP has obtained rights to use the mSEPT9 biomarker to ...
